Illustrative image – not actual.KKR & Co LP, US private equity firm, is planning to acquire minority stake in Gland Pharma.
The acquisition is valued at $200 million (approx Rs 1,247.6 crore). However, the acquisition is subject to regulatory approvals.
KKR will acquire the minority stake in Gland Pharma, including the entire stake held by private equity fund, Evolvence India Life science Fund, in Gland Pharma. The size of the stake has not yet been disclosed by the companies.
Gland Pharma develops and manufactures generic injectables primarily for selling in the US market and also for India and some other markets.
